Peyronie's: Researchers give nod to autologous grafts
Las Vegas- In their first experiences with xenografts for Peyronie's disease, surgeons at the Mayo Clinic in Jacksonville, FL, decided that Surgisis (Cook Biotech Incorporated, West Lafayette, IN) worked better than Tutoplast (IOP, Inc., Costa Mesa, CA), but the surgeons said they still prefer autologous grafts.
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.